Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 54
Filter
1.
Cancer Chemother Pharmacol ; 69(5): 1289-99, 2012 May.
Article in English | MEDLINE | ID: mdl-22302407

ABSTRACT

BACKGROUND: We present a comprehensive analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations in advanced non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors (TKIs), with the aim of clarifying the relative contribution of these molecular alterations to resistance. PATIENTS AND METHODS: One hundred and sixty-six patients with advanced NSCLC treated with EGFR-TKIs with available archival tissue specimens were included. EGFR (exons 18-21), KRAS (exons 2, 3), PIK3CA (exons 9, 20), and MET (exons 14, 15) mutations were analyzed using PCR-based sequencing. Among all the mutations evaluated, only KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations, defined as "TKI non-sensitizing mutations" were used for response, time to progression (TTP), and overall survival (OS) analysis. RESULTS: TKI non-sensitizing mutations were associated with disease progression (p = 0.001), shorter TTP (p < 0.0001), and worse OS (p = 0.03). Cox's multivariate analysis including histology and performance status showed that TKI non-sensitizing mutations were independent factors for shorter TTP (p < 0.0001) and worse OS (p = 0.01). CONCLUSIONS: When KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations are concomitant, up to 96.0% of NSCLC patients unlikely to respond to TKIs can be identified, and they represented independent negative prognostic factors. Comprehensive molecular dissection of EGFR signaling pathways should be considered to select advanced NSCLC patients for TKIs therapies.


Subject(s)
Carcinoma, Non-Small-Cell Lung/drug therapy , Drug Resistance, Neoplasm/genetics , Lung Neoplasms/drug therapy , Patient Selection , Protein Kinase Inhibitors/therapeutic use , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Class I Phosphatidylinositol 3-Kinases , ErbB Receptors/genetics , Female , Follow-Up Studies , Humans , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Male , Middle Aged , Multivariate Analysis , Mutation , Phosphatidylinositol 3-Kinases/genetics , Prognosis , Proportional Hazards Models , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins c-met/genetics , Proto-Oncogene Proteins p21(ras) , Retrospective Studies , Survival Analysis , Time Factors , Treatment Outcome , ras Proteins/genetics
2.
J Endocrinol Invest ; 32(5): 440-4, 2009 May.
Article in English | MEDLINE | ID: mdl-19494709

ABSTRACT

BACKGROUND: The high prevalence of thyroid nodules in iodine-deficient areas is a practical problem because of the large number of patients requiring fine needle aspiration (FNA) to detect malignant nodules. AIM: To obtain an ultrasound (US) score for predicting malignant nodules and reduce the number of unnecessary and expensive FNA. SUBJECT AND METHOD: All nodules observed from September 2001 to March 2006 were evaluated by US: echostructure, echogenicity, halo, microcalcifications and ratio between antero-posterior and transversal diameters (AP/TR). Two thousand six hundred and forty-two consecutive patients underwent US-guided FNA for a total of 3645 nodules. RESULTS: Logistic regression analysis showed a potent predictive role for solitary nodules and absence/ incomplete halo (p=0.000). A significant predictive role for microcalcifications and AP/TR ratio was also observed. A 10-point score was constructed using the standardized regression coefficient. Nodules with US score or=5.5 had a frequency of malignancy of 0.4, 1.1 and 5.6% (p<0.001), respectively. Nodules with >or=5.5 US score were characterized by a 66% sensitivity and a 76% specificity compared to the diagnostic values of single parameters which were either sensitive or specific. CONCLUSIONS: According to our data, we suggest FNA for nodules reaching a >5.4 US score, whereas a clinical judgement should be used for the intermediate category nodules. When the score is lower than 2.5 we do not recommend FNA. The practical use of this US score can help reduce unnecessary and expensive FNA in iodine-deficient areas.


Subject(s)
Iodine/deficiency , Thyroid Nodule/diagnostic imaging , Thyroid Nodule/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Biopsy, Fine-Needle , Child , Child, Preschool , Female , Humans , Italy/epidemiology , Male , Middle Aged , Predictive Value of Tests , Prevalence , Research Design , Thyroid Nodule/classification , Thyroid Nodule/epidemiology , Ultrasonography, Doppler, Color , Young Adult
3.
J Endocrinol Invest ; 31(4): 303-8, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18475047

ABSTRACT

OBJECTIVE: Liquid-based cytology using the thin layer technique has recently been introduced in thyroid fine needle aspiration cytology together with or in substitution of direct smears, but its usefulness is still controversial and relatively few studies have been published in this field. The aim of the present study was to compare the results obtained from conventional smears with those from thin layer smears. DESIGN: In 3875 thyroid nodules, a double cytologic sampling was taken in randomized order, to prepare conventional or thin layer smears. MAIN OUTCOME: The diagnoses agreed in 2934 (75.7%) cases and disagreed in 941 (24.3%). The analysis of discordant data showed there were fewer non-diagnostic cases in the thin layer smears (377 vs 541, p<0.001) whereas in conventional smears there were more cases positive for carcinoma (27 vs 4, p<0.001). The cytohistologic correlation was available for 194 cases and showed that conventional smears had a greater capacity for revealing carcinomas (44 vs 31). Finally, diagnoses based on conventional smears were more sensitive than thin layer smears (93.6% vs 65.9%) whereas specificity was constant. CONCLUSIONS: From our experience, the conventional smear offers a greater possibility of diagnosis when suspecting malignancy or diagnosing malignancy cases, whereas thin layer smears significantly reduce the number of non-diagnostic cases. For this reason, we suggest combining the two techniques in routine cytologic diagnosis.


Subject(s)
Biopsy, Fine-Needle/methods , Biopsy, Fine-Needle/standards , Thyroid Nodule/pathology , Biopsy, Needle/standards , Histocytochemistry/instrumentation , Histocytochemistry/methods , Humans , Thyroid Nodule/chemistry , Thyroid Nodule/diagnosis
4.
Vox Sang ; 95(4): 308-12, 2008 Nov.
Article in English | MEDLINE | ID: mdl-19138260

ABSTRACT

BACKGROUND AND OBJECTIVE: Intraoperative autologous blood recovery during radical retro pubic prostatectomy has the potential of contamination with tumour cells. Its safety is proved by similar survival rates between allogeneic and autologous transfusion to oncology patients without standardization. Silencing of the gene encoding pi class of gluthatione-S transferase is a specific and sensitive molecular marker for prostate cancer, because it is present in more than 90% of prostate tumours. Using such tumour marker, we aimed to demonstrate that viable tumour cells could be eliminated using leucodepletion filters followed by irradiation. MATERIALS AND METHODS: Fifty patients with pi class of gluthatione-S transferase promoter hypermethylation in their primary prostate tumours were included in the analysis. Peripheral blood samples were collected during anaesthetic induction and recovered blood was collected throughout the surgery and then submitted to washing, leucoreduction and irradiation. Samples were analysed stepwise for the presence of promoter hypermethylation using real-time methylation-specific polymerase chain reaction. RESULTS: Positive hypermethylation was found in recovered blood (two samples), recovered and washed blood (three samples), and recovered washed and filtered blood (two samples). After filtration and irradiation of the recovered blood, this marker could not be detected in any of the cases analysed, suggesting the absence of viable tumour cells. CONCLUSION: Even though the risk of disseminating tumour cells in prostate cancer surgery by intraoperative autologous blood recovery is not yet fully established, no tumour-specific gene amplification was found after the association of blood filtration and irradiation, suggesting a significant reduction of such risk.


Subject(s)
Blood Loss, Surgical , Blood Transfusion, Autologous/methods , Prostatic Neoplasms/surgery , Biomarkers, Tumor/analysis , DNA Methylation , Glutathione S-Transferase pi/genetics , Humans , Intraoperative Care , Leukocyte Reduction Procedures , Male , Neoplastic Cells, Circulating , Promoter Regions, Genetic , Survival Rate
5.
Phys Rev Lett ; 96(24): 246405, 2006 Jun 23.
Article in English | MEDLINE | ID: mdl-16907263

ABSTRACT

The resonant multiple Bragg x-ray diffraction is used to study the forbidden (104) reflection in LaMnO3. Using the interference between the three-beam scattering and resonant scattering we can determine the phase of the resonant scattering. This phase is shown to be consistent with a model in which the resonant scattering is caused by the influence of the Mn-O bond length distortion rather than directly by the orbital ordering on the Mn 4p band structure.

6.
Pathologica ; 97(3): 137-40, 2005 Jun.
Article in Italian | MEDLINE | ID: mdl-16259281

ABSTRACT

Angiomyolipoma is a lesion usually observed in the kidney of patients with tuberous sclerosis. Extrarenal sites are very unusual with sporadic cases in internal organ, soft tissue and skin (fifteen cases have been described in this site). Herein we describe an adding case located on the ear in 58-year-old man reviewing the pertinent literature. The main diagnostic differential criteria are also discussed.


Subject(s)
Angiomyolipoma/pathology , Ear Neoplasms/pathology , Ear, External/pathology , Skin Neoplasms/pathology , Actins/analysis , Angiomyolipoma/diagnosis , Angiomyolipoma/surgery , Biomarkers, Tumor/analysis , Diagnosis, Differential , Ear Neoplasms/diagnosis , Ear Neoplasms/surgery , Ear, External/surgery , Humans , Male , Middle Aged , Neoplasm Proteins/analysis , Skin Neoplasms/diagnosis , Skin Neoplasms/surgery
7.
Biotech Histochem ; 79(3-4): 121-7, 2004.
Article in English | MEDLINE | ID: mdl-15621884

ABSTRACT

Cathepsins L and B are lysosomal cysteine proteinases whose activities and cellular location are altered in many types of cancers and cancer cell lines. Cathepsins L and B play an unspecified role in cancer invasion and metastasis. The purpose of our study was to determine whether cathepsins L and B are important for the ability of two prostate cancer cell lines, PC3 and DU 145, to invade the basement membrane-like preparation, Matrigel. Exposure of PC3 and DU145 to the irreversible cysteine proteinase inhibitor, E64, decreases the invasive ability of DU145, but not PC3. PC3 and DU145 were treated with the phorbol ester analogue, phorbol 12-myristate 13-acetate (PMA), a known tumor promoter that activates protein kinase C and contributes to the metastatic phenotype. PMA increased secreted cathepsin L+B activity and the invasive ability of PC3 and DU145; co-exposure to E64 and PMA decreased both cathepsin L+B activity and invasion. We conclude that DU145 requires cathepsin L+B activity more than PC3 for the invasion of the Matrigel. When the amount of secreted cathepsin L+B activity is increased by PMA treatment, however, PC3 becomes dependent on cathepsin L+B for invasion. Our study demonstrates that modulation of the amount of secreted cathepsin L+B activity influences the invasive phenotype of PC3 and DU145.


Subject(s)
Cathepsin B/metabolism , Cathepsins/metabolism , Collagen , Cysteine Endopeptidases/metabolism , Drug Combinations , Laminin , Neoplasm Invasiveness/pathology , Neoplasm Invasiveness/physiopathology , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Proteoglycans , Cathepsin B/drug effects , Cathepsin L , Cathepsins/drug effects , Cell Count/methods , Cell Line, Tumor , Cell Movement , Cell Proliferation , Cysteine Endopeptidases/drug effects , Humans , Male , Neoplasm Staging/methods , Tetradecanoylphorbol Acetate
8.
Transfus Med ; 14(2): 151-5, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15113379

ABSTRACT

Intra-operative autologous blood recovery offers many advantages. However, blood salvage during cancer surgery is of limited use due to the potential presence of circulating tumour cells. It was the aim of this study to show that intra-operative salvage blood can be freed of cells and cellular DNA after leucoreduction by filtration and irradiation of washed blood. Known amounts of tissue culture derived from carcinoma, melanoma and osteosarcoma were added to whole blood bags. This mixture was then submitted to washing, leucoreduction and irradiation. Samples were studied stepwise in relation to the integrity and size of DNA by the polymerase chain reaction (PCR). After filtration and irradiation, PCR targeting the beta-globin gene (268 bp amplicon) was negative. Our results were corroborated by studying plasma samples added with tumoural cells. Using PCR methodology, we showed the absence of DNA from cells in experimentally contaminated blood and plasma bags after filtration and irradiation. This experimental study is an effort to ensure the safety of intra-operative autologous transfusion.


Subject(s)
Blood Cells/radiation effects , Blood Transfusion, Autologous/standards , Leukocyte Reduction Procedures , Neoplasms/therapy , Neoplastic Cells, Circulating/pathology , Blood Cells/pathology , Blood Transfusion, Autologous/methods , DNA, Neoplasm/analysis , Filtration , Globins/genetics , Humans , Models, Biological , Neoplasms/pathology , Neoplastic Cells, Circulating/radiation effects , Polymerase Chain Reaction
9.
Biotech Histochem ; 78(2): 101-8, 2003 Apr.
Article in English | MEDLINE | ID: mdl-14533846

ABSTRACT

Cancer metastasis involves multiple factors, one of which is the production and secretion of matrix degrading proteases by the cancer cells. Many metastasizing cancer cells secrete the lysosomal proteases, cathepsins L and B, which implicates them in the metastatic process. Cathepsins L and B are regulated by endogenous cysteine proteinase inhibitors (CPI) known as cystatins. An imbalance between cathepsin L and/or B and cystatin expression/activity may be a characteristic of the metastatic phenotype. To determine whether cystatins can attenuate the invasive ability of PC3 prostate cancer cells, cells were transfected with a cDNA coding for chicken cystatin. Expression of chicken cystatin mRNA was determined by PCR analysis. Total cysteine proteinase inhibitory activity, cathepsins L + B activity, and invasion through a Matrigel matrix were assessed. Stably transfected cells expressed the chicken cystatin mRNA and exhibited a significant decrease in secreted cathepsin L + B activity and a small increase in secreted cysteine proteinase inhibitor activity. The ability of cystatin transfected cells to invade the reconstituted basement membrane, Matrigel, was attenuated compared to nontransfected cells or cells transfected with vector alone. We have demonstrated that the cysteine proteinases cathepsins L and B participate in the invasive ability of the PC3 prostate cancer cell line, and we discuss here the potential of using cysteine proteinase inhibitors such as the cystatins as anti-metastatic agents.


Subject(s)
Cathepsin B/metabolism , Cathepsins/metabolism , Cystatins/metabolism , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Cathepsin B/antagonists & inhibitors , Cathepsin L , Cathepsins/antagonists & inhibitors , Cell Line, Tumor , Cell Movement , Collagen , Cystatins/genetics , Cysteine Endopeptidases , Drug Combinations , Humans , Laminin , Male , Neoplasm Invasiveness , Proteoglycans , Recombinant Proteins/metabolism , Transfection
10.
Acta Crystallogr A ; 58(Pt 4): 385-90, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12089461

ABSTRACT

A number of X-ray reflections from an icosahedral quasicrystal Al-Pd-Mn have been measured with great accuracy on an absolute basis by making use of Bragg-case diffraction. Since the specimen had high crystal quality, the dynamical theory was used for analyzing the results and to extract structure factors from measured integrated intensities. Good agreement was found between theory and experiment for strong reflections. Anomalous transmission was found to be strong in the 'good' regions of the quasicrystalline specimen and it was measured on an absolute basis, but the small residual strains present in the specimen prevented an accurate comparison between theory and experiment. A detailed discussion is presented on the parameters that mostly affect anomalous transmission in relationship to the adopted structural model.

11.
Brain Res Dev Brain Res ; 121(1): 1-9, 2000 May 11.
Article in English | MEDLINE | ID: mdl-10837887

ABSTRACT

The ganglioside GM1 is a glycosphingolipid which enhances process formation of several neuronal lines and potentiates some growth factor-mediated responses. Previously we have shown that 24 h exposure of Neuro 2a cells to GM1 mobilized the neuron-specific microtubule-associated protein, MAP2, away from microtubule-rich areas to areas of neurite sprouting where MAP2 was more closely associated with the subcortical actin network. To examine the role of GM1 in fostering the shift of the association of MAP2 from tubulin to actin, NIH 3T3 cells were co-transfected with pHook-1, which expresses a surface antigen, and a construct expressing MAP2. Transfected cells were selected with magnetic beads coated with a hapten that binds to the expressed surface antigen and treated with 150 microg/ml GM1 for 18-24 h. Actin and MAP2 or tubulin and MAP2 were immunolocalized and examined with confocal microscopy. MAP2 was found throughout the cytoplasm as well as associated with actin filaments. As observed previously with Neuro 2a, GM1 treatment of transfected fibroblasts redistributed the MAP2 away from direct association with microtubules to peripheral areas where the association of MAP2 with actin was enhanced. GM1 did not induce neurite-like processes in MAP2-transfected cells. Treatment with cytochalasin B, which is reported to result in process formation, also did not induce neurite-like processes. These studies suggest that GM1's ability to mobilize MAP2 and promote its association with actin is not restricted to neurons.


Subject(s)
Actins/metabolism , G(M1) Ganglioside/metabolism , Microtubule-Associated Proteins/metabolism , 3T3 Cells , Animals , Cloning, Molecular , Fluorescent Antibody Technique , Mice , Microtubule-Associated Proteins/genetics , Microtubules/metabolism , Neurons/metabolism , Transfection , Tubulin/metabolism
12.
Int J Dev Neurosci ; 18(8): 797-805, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11154849

ABSTRACT

To investigate mechanisms of neurite outgrowth, murine Neuro-2a neuroblastoma cells were exposed to ganglioside GM1 in the presence or absence of specific protein kinase inhibitors. Isoquinolinesulfonamide (H-89), an inhibitor of cyclic AMP dependent protein kinase A (PKA), and bisindolylmaleimide I (BIM), which inhibits protein kinase C, each stimulated neurite outgrowth in a dose-dependent manner in the absence of exogenous GM1. Minimally effective (threshold) concentrations of H-89 or BIM potentiated outgrowth when they were used in combination with GM1. To search for a shared component in the mechanisms of GM1, H-89 and BIM, phosphorylation of ERK1/2 was examined. Inhibition of the activation of extracellular signal regulated kinases (ERK1/2) by U0126, prevented neuritogenesis of Neuro-2a by all the three agents. Pretreatment of serum-depleted Neuro-2a cultures with GM1 or BIM enhanced ERK1/2 phosphorylation when the serum level was restored to 10%. In contrast, H-89 did not alter the serum-mediated response. In cells exposed to GM1 or BIM without additional serum, a transitory decrease in ERK phosphorylation occurred. These data suggest that GM1 influences two neuritogenic pathways, one modulated by PKC and the other regulated by PKA. Therefore, GM1 may have the potential to stimulate alternate pathways resulting in outgrowth.


Subject(s)
G(M1) Ganglioside/pharmacology , MAP Kinase Signaling System/physiology , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinases/metabolism , Neurites/enzymology , Sulfonamides , Animals , Enzyme Inhibitors/pharmacology , Indoles/pharmacology , Isoquinolines/pharmacology , MAP Kinase Signaling System/drug effects , Maleimides/pharmacology , Mice , Mitogen-Activated Protein Kinase 3 , Neuroblastoma , Phosphorylation , Tumor Cells, Cultured
13.
Brain Res Dev Brain Res ; 105(2): 227-39, 1998 Feb 10.
Article in English | MEDLINE | ID: mdl-9541741

ABSTRACT

In previous studies, we demonstrated that the exogenous ganglioside GM1 increased the complexity of the microtubular network and level of tubulin, selectively changed the distribution of microtubule associated protein-2 (MAP2) immunoreactivity from the perikarya to distal neuritic processes and increased immunogold label of MAP2 in the subplasmalemmal cytoplasm, neuritic filopodia and growth cones of Neuro-2a neuroblastoma cells. Since these areas are rich in actin filaments, our data suggested that MAP2 may be associated with microfilaments in the early stages of ganglioside-induced neuritogenesis. To determine if GM1 alters neuronal morphology by facilitating the interaction of actin and MAP2, we examined the immunolocalization of these two proteins with confocal and electron microscopy. We found that along with the redistribution of MAP2 from perikaryal to neuritic regions, there was parallel redistribution of actin. The uniform subplasmalemmal actin meshwork was disrupted in areas of processes and filopodia with a redistribution of actin to these areas in close association with MAP2. Our present results suggest that gangliosides enhance neuritogenesis by redistributing actin as well as MAP2 to processes and filopodia thereby facilitating their interaction. The association of MAP2 with actin filaments is likely to be an early step in ganglioside-mediated filopodia formation.


Subject(s)
Actins/metabolism , G(M1) Ganglioside/pharmacology , Microtubule-Associated Proteins/metabolism , Microtubules/metabolism , Microtubules/ultrastructure , Neurons/metabolism , Neurons/ultrastructure , Animals , Blotting, Northern , Blotting, Western , Cell Line , Fluorescent Antibody Technique, Direct , Mice , Microscopy, Fluorescence , Microscopy, Immunoelectron , Microtubules/drug effects , Models, Neurological , Neurons/drug effects , RNA, Messenger/biosynthesis , RNA, Messenger/genetics
14.
Ann Emerg Med ; 28(3): 309-12, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8780474

ABSTRACT

STUDY OBJECTIVE: To determine how accurately paramedics interpret common lung sounds on an audiotape in comparison with emergency physicians. METHODS: We carried out a prospective comparison of blinded lung sound interpretation using a standard teaching tape. Our subjects were 67 experienced paramedics and 22 new paramedics from urban and suburban emergency medical services systems comprising municipal and private ambulance providers; and 18 emergency physicians. Five common lung sounds were played three times, in different sequences, and with additional patient history provided for each repetition. The members of each group listened to the same tape and were asked to identify the lung sounds. RESULTS: Emergency physicians had a median score of five of five possible correct responses in each of the three trials. This score was significantly higher than those of experienced and new paramedics. Experienced paramedics (P = .001) and new paramedics (P = .002) significantly increased their median scores over the three trials with additional medical history. We found no significant difference between experienced and new paramedics in any of the three trials. CONCLUSION: In our study, paramedics did not assess lung sounds as accurately as emergency physicians, and experienced paramedics did not interpret sounds more accurately than new paramedics. Correct identification of lung sounds improved significantly for paramedics when medical history was known.


Subject(s)
Auscultation , Emergency Medical Technicians , Respiratory Sounds/diagnosis , Clinical Competence , Emergency Medicine , Humans , Prospective Studies
16.
Exp Neurol ; 139(1): 1-11, 1996 May.
Article in English | MEDLINE | ID: mdl-8635555

ABSTRACT

The effect of ganglioside GM1 on components of the neuronal cytoskeleton was studied in Neuro-2a neuroblastoma cells using immunofluorescent, immunogold-labeled, and Western-blot analysis. Exposure of cells to GM1 for 24 h resulted in an increased microtubular network and level of tubulin, a redistribution of MAP2 immunoreactivity from perikarya to distal neuritic processes, and an increased MAP2 gold label in the subplasmalemmal cytoplasm, neuritic spines, and growth cones. A similar change in the distribution of actin-positive fluorescent immunoreactivity was observed. In contrast to the redistribution of MAP2, immunolocalization of MAP5 and tau did not change following 24 h GM1 exposure. Our results suggest that gangliosides enhance neuritogenesis by selectively altering the distribution of MAP2 from perikaryon to neuritic spines. Furthermore, the enhanced presence of MAP2 in regions known to be rich in microfilaments following GM1 treatment suggests that an interaction of MAP2 with microfilaments may be necessary for early neurite formation.


Subject(s)
G(M1) Ganglioside/pharmacology , Microtubule-Associated Proteins/drug effects , Microtubules/drug effects , Actins/analysis , Animals , Base Sequence , Blotting, Western , Fluorescent Antibody Technique , Mice , Microscopy, Immunoelectron , Microtubule-Associated Proteins/analysis , Molecular Sequence Data , Neuroblastoma , Neurons/chemistry , Neurons/cytology , Neurons/ultrastructure , Tumor Cells, Cultured/chemistry
18.
J Clin Oncol ; 13(10): 2497-502, 1995 Oct.
Article in English | MEDLINE | ID: mdl-7595699

ABSTRACT

PURPOSE: To assess the effect of treatment intensification and that of extended intrathecal methotrexate substitution for cranial irradiation in intermediate-risk acute lymphoblastic leukemia (ALL) children treated with a Berlin-Frankfurt-Münster (BFM)-based intensive chemotherapy. PATIENTS: Three hundred ninety-six children with non-B-ALL were enrolled onto the Associazione Italiana di Ematologia ed Oncologic Pediatrica (AIEOP) ALL 88 study. Standard risk (SR) included patients with low tumor burden (BFM risk index [RI], < 0.8); intermediate risk (IR) were patients with an RI > or = 0.8 but less than 1.2; and high risk (HR) were those with an RI > or = 1.2 or CNS involvement at diagnosis. The treatment schedule was a modified version of the ALL-BFM 86 study. CNS-directed treatment consisted of high-dose methotrexate (HD-MTX; 5 g/m2 for four courses) plus intrathecal methotrexate (IT-MTX; nine doses); IR patients additionally received extended IT-MTX (nine doses during continuation therapy); cranial irradiation was given only to HR patients. RESULTS: Of the 375 (94.7%) children who achieved remission, 1.3% had an adverse event other than relapse. The estimated event-free survival (EFS) at 6 years was 66.6% (SE 2.4) overall; 80.7% (4.5) in the SR patients, 77.5% (3.9) in the IR patients, and 54.5% (3.7) in the HR patients. Relapse occurred in 107 children (27.0%). Isolated CNS relapse occurred in 20 children (5.0%): 5 (6.3%) in the SR group, 1 (0.8%) in the IR group, and 14 (7.1%) in the HR group. The estimated 6-year CNS leukemia-free survival was 94.6% (1.2) overall: 93.5% (2.8) in the SR group, 99.1% (0.9) in the IR group, and 92.3% (2.0) in the HR group. CONCLUSION: Cranial irradiation may be omitted safely in IR ALL patients treated with BFM-based intensive chemotherapy when extended intrathecal chemotherapy is given. Because the CNS disease control was less complete in the SR group, these data challenge the effectiveness of HD-MTX for protection from CNS disease and support the protective role of extended intrathecal chemotherapy.


Subject(s)
Antimetabolites, Antineoplastic/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Brain Neoplasms/prevention & control , Cranial Irradiation , Methotrexate/administration & dosage , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/radiotherapy , Adolescent , Asparaginase/administration & dosage , Child , Child, Preschool , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Cytarabine/administration & dosage , Daunorubicin/administration & dosage , Female , Humans , Infant , Injections, Spinal , Male , Mercaptopurine/administration & dosage , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Prednisone/administration & dosage , Recurrence , Regression Analysis , Remission Induction , Survival Analysis , Vincristine/administration & dosage
19.
Med Pediatr Oncol ; 25(1): 12-6, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7752996

ABSTRACT

Optimal treatment for Langerhans Cell Histiocytosis (LCH) has not yet been established. Preliminary reports suggest some effect of cyclosporine (CSA), both alone or in combination with steroids and/or vinblastine, in untreated cases. Twelve children (6 females and 6 males, age at diagnosis 3 months to 4 years) with biopsy proven, systemic LCH received oral CSA (12 mg/kg/day in two divided doses given daily) as a second-line therapy following chemotherapy including vinblastine and/or etoposide (10 cases) or steroid alone (one case); one child was not pretreated. A total of 16 CSA courses were administered to the 12 patients: 8 were completed, 4 were interrupted as unsuccessful, and 4 are still ongoing. CSA related toxicity consisted of hypertrichosis and transient hypertension and was never limiting. Treatment was associated with a clinical response in 8/12 patients: 3 had a complete response and are off therapy, and 5 had a partial response; disease reactivation following first favorable response required additional CSA courses in 3 patients. Four patients failed to respond to CSA: two died of progressive disease, while two had a favorable response to CSA + VP16. Favorable response to CSA was not related to CSA trough and peak levels and was usually observed during the first 2 weeks of CSA therapy. CSA is effective for treatment of LCH also in pretreated children with progressive disease including life-threatening organ dysfunction. Long-lasting complete remission may be achieved after 6 to 12 months of CSA therapy. When disease reactivation occurs after treatment withdrawal, a second course may be followed by favorable response. As minimal or no adverse effects are observed during or after prolonged CSA therapy, this may also be safely used in young patients.


Subject(s)
Cyclosporine/therapeutic use , Histiocytosis, Langerhans-Cell/drug therapy , Child , Child, Preschool , Drug Resistance , Female , Humans , Infant , Male
20.
Cancer ; 75(7): 1684-93, 1995 Apr 01.
Article in English | MEDLINE | ID: mdl-8826928

ABSTRACT

BACKGROUND: Improved outcome of children with acute lymphoblastic leukemia (ALL) who received intensive chemotherapy was observed by the Italian Association for Pediatric Hematology Oncology (AIEOP). To verify if this improved outcome was also extended to T-cell acute lymphoblastic leukemia (T-ALL) patients after introduction of intensive chemotherapy, treatment responses of 2011 patients, including 184 with T-ALL treated over the decade 1982-1991, were analyzed. Further, the potential use of the association of presenting clinical and biologic features with treatment outcome to determine risk factors that might be useful for planning risk-directed therapeutic studies was analyzed. METHODS: Of the 2011 children consecutively entered on the three sequential AIEOP trials ('82, '87, and '88), 1528 (76%) had successful immunologic studies of the bone marrow blasts. One hundred eighty-four (12%) had T-ALL. During these studies, four consecutive high-risk ALL treatment protocols (i.e., 8303, 8503, 8703, and 8803) were used. Because the treatment schedule in protocols 8503 and 8703 were almost identical, those patients were grouped together for the purpose of survival analysis. The 137 boys and 47 girls ranged in age from 16 months to 15.5 years (median, 7.8 years) at diagnosis, and 38% had a mediastinal mass. The rates of treatment response [i.e. complete remission (CR) and event free survival (EFS) rates] were compared for patients with T-ALL or B-cell progenitor ALL, overall and by individual study. Presenting features and early response to steroid monotherapy were also tested as possible prognostic factors. RESULTS: Overall, the CR rate was 94%, and the 7-year survival (SE) was 51.9% (4.2). T-ALL patients had a significantly worse outcome than B-lineage ALL patients [7-year EFS 40.4% (5.2) vs. 61.7% (1.7), P < 0.001]. Progressive improvement in EFS for T-ALL patients treated during 1 decade was observed, with 7-year EFS (SE) of 23.2% (8.3) for protocol 8303, 5-year EFS of 39.5% (7.1) for combined protocols 8503-8703, and 54.6% (7.1) for study '88, respectively. The analysis of prognostic factors for T-ALL patients showed that poor in vivo steroid response was the most unfavorable prognostic factor, followed by leukocyte level count > 50 x 10(9)/l (P = 0.04). The EFS for patients with T-ALL and good steroid response [63% (3.0)] was comparable with that of the unselected B-lineage ALL patients. CONCLUSIONS: EFS for patient with T-ALL has steadily increased in consecutive AIEOP ALL trials. However T-ALL patients still have a significantly worse EFS compared with patients with B-lineage ALL. Patients with T-ALL and a poor in vivo response to steroid monotherapy represent a particularly high risk treatment group.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Leukemia-Lymphoma, Adult T-Cell/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Leukemia-Lymphoma, Adult T-Cell/mortality , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Prognosis , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...